Printer Friendly

Bioniz Therapeutics Provides Results from Multi-Cytokine Inhibitor BNZ-1 Clinical Study.

M2 PHARMA-July 20, 2017-Bioniz Therapeutics Provides Results from Multi-Cytokine Inhibitor BNZ-1 Clinical Study

(C)2017 M2 COMMUNICATIONS

- Irvine, California-based peptide therapeutics developer Bioniz Therapeutics, Inc. has released top-line results from its first-in-human study of BNZ-1, a novel IL-2/IL-9/L-15 inhibitor, the company said.

In the open-label, dose-escalation study (NCT03046459), 18 healthy volunteers were administered a single intravenous dose of BNZ-1 ranging from 0.2 mg/kg to 6.4 mg/kg followed by 30 days of safety monitoring and collection of pharmacokinetic and biomarker samples.

BNZ-1 was well-tolerated and generally considered safe, without any clinically significant laboratory abnormalities or dose limiting toxicities observed at any dose level.

Bioniz will initiate a multiple ascending dose study of BNZ-1 in healthy volunteers in Q3 2017 and plans to conduct future clinical trials of BNZ-1 in multiple patient populations, including the T-cell malignancies of Large Granular Lymphocyte Leukemia and Cutaneous T-cell Lymphoma, as well as for autoimmune indications, including Alopecia Areata.

The company's lead development candidate, BNZ-1, is a PEGylated peptide that functions as a selective and simultaneous inhibitor of cytokines IL-2, IL-9, and IL-15.

Bioniz is a clinical-stage biopharmaceutical company developing multi-cytokine inhibitory peptide therapeutics to address immuno-inflammatory diseases and cancer.

The company leverages its world class expertise in cytokine biology, originating in research conducted at the National Institutes of Health, to develop a novel approach to selectively inhibit functionally redundant cytokines while leaving the rest of the cytokine network intact.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Clinical report
Date:Jul 20, 2017
Words:251
Previous Article:Imago BioSciences Begins Phase 2a of Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Next Article:CSL Behring's Supplemental Biologics License Application for Hizentra for CIPD Accepted for Review by FDA.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters